Tom 16, Nr 4 (2019)
Farmakoterapia chorób układu krążenia
Opublikowany online: 2019-12-02
Komentarz — riwaroksaban 2,5 mg + ASA w wytycznych ESC 2019
Choroby Serca i Naczyń 2019;16(4):220-221.
Streszczenie
Brak
Referencje
- Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
- Motovska Z, Hlinomaz O, Kala P, et al. PRAGUE-18 Investigators, PRAGUE-18 Study Group. Prasugrel versus ticagrelor in patients mith acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation. 2016; 134(21): 1603–1612.
- Motovska Z, Hlinomaz O, Kala P, et al. PRAGUE-18 Study Group. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018; 71(4): 371–381.
- Schüpke S, Neumann FJ, Menichelli M, et al. ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019; 381(16): 1524–1534.